Unlocking SpA Insights: How Enthesitis Assessments are Shaping Personalized Treatment
"A deep dive into the ABILITY-2 trial reveals the power of targeted enthesitis evaluation for effective spondyloarthritis management and improved patient outcomes."
Spondyloarthritis (SpA) is a chronic inflammatory condition that primarily affects the spine, but can also involve peripheral joints, entheses (the sites where tendons and ligaments attach to bone), and other organs. This complexity makes SpA a challenging condition to diagnose and manage, necessitating a multifaceted approach to treatment.
Enthesitis, inflammation at the entheses, is a hallmark feature of SpA. It contributes significantly to pain, stiffness, and functional limitations experienced by individuals with the condition. However, assessing enthesitis can be challenging in clinical practice, and there is no universally accepted method for its evaluation. This lack of standardization has hindered the development of targeted therapies and personalized treatment strategies.
Fortunately, recent research is shedding light on the importance of enthesitis assessment in SpA. The ABILITY-2 trial, a multicenter phase 3 study, has provided valuable insights into the use of various enthesitis assessment tools during adalimumab (ADA) treatment of non-psoriatic peripheral SpA (pSpA). This article will delve into the findings of the ABILITY-2 trial, exploring how enthesitis assessments can guide treatment decisions and ultimately improve patient outcomes.
Burden Across SpA
Enthesitis indices assess different anatomical locations, so they can identify different numbers of patients with enthesitis across spondyloarthritis subtypes. The Danish nationwide DANBIO registry examined the registration, pattern, and burden of clinical enthesitis among routine-care patients with psoriatic arthritis and axial spondyloarthritis. This variation in assessment sites is important when interpreting prevalence and disease burden across SpA populations.
Assessment Challenges
Clinical enthesitis assessment generally relies on examining symptomatic or commonly affected tendon, ligament, and joint-capsule attachment sites. However, methods may differ in the locations they evaluate, which can produce different estimates of enthesitis across SpA subtypes. These limitations support cautious interpretation when comparing findings between assessment approaches.
From Enthesis to Pathogenesis
Early pathological descriptions placed the enthesis at the center of efforts to understand spondyloarthritis. Contemporary high-performance imaging, including magnetic resonance imaging, provided new insights into the sequence leading to entheseal ossification. This work also highlighted the synovio-entheseal complex as a possible driver of arthritis and renewed interest in the enthesis as a pathogenic site.
Deciphering Enthesitis Assessments: What the ABILITY-2 Trial Reveals
The ABILITY-2 trial aimed to evaluate the efficacy of adalimumab (ADA) on enthesitis and compare different enthesitis patterns and tools in patients with peripheral SpA (pSpA). The study enrolled patients aged 18 years and older who fulfilled the Assessment of SpondyloArthritis international Society (ASAS) peripheral SpA criteria and had active disease. Participants were randomized to receive ADA 40 mg every other week or placebo (PBO) for 12 weeks, followed by a 144-week open-label extension. Enthesitis was assessed at 29 sites based on the Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), and Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) through week 104.
- At baseline, 87% of patients had at least one enthesitis site.
- The Leeds Enthesitis Index (LEI) was positive in 72.0% of patients, SPARCC in 90.2%, and MASES in 86.0%.
- The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) question regarding enthesitis failed to discriminate between those with and without enthesitis at baseline.
- The LEEDS score showed better discriminatory power between ADA-treated and PBO-treated patients at week 12 compared to SPARCC or MASES.
Evolving Enthesitis Research
Recent reviews continue to examine enthesitis as a central feature of spondyloarthritis, including its possible role in disease initiation and its contribution to symptoms. The literature also considers how enthesitis affects patients with psoriatic arthritis and axial spondyloarthritis. Treatment remains an important focus because controlling enthesitis is linked to achieving remission or minimal disease activity.
Limits of Measurement
Enthesitis assessment is not a single uniform process, because different indices evaluate different anatomical locations. As a result, two approaches may identify different numbers of patients with enthesitis. Comparisons between studies therefore require attention to the sites and methods used rather than assuming that all enthesitis measures are interchangeable.
Comparing Assessment Strategies
Comparative interpretation is complicated by variation in the locations included in enthesitis indices. An index that evaluates one set of attachment sites may identify a different patient group from an index using another set. This makes direct comparisons across SpA subtypes or studies more difficult and favors describing the assessment sites alongside the results.
Personalizing SpA Treatment: The Future of Enthesitis Assessment
The ABILITY-2 trial underscores the importance of incorporating enthesitis assessments into the management of SpA. By carefully evaluating enthesitis using validated tools like the LEEDS and SPARCC, clinicians can gain a more comprehensive understanding of disease activity and tailor treatment strategies accordingly.
Clinical Importance
Enthesitis is reported as a common manifestation of axial spondyloarthritis and psoriatic arthritis, occurring in up to 40% of patients with SpA. Its clinical relevance is reflected in its role as a major criterion in many classification systems for these diseases. The DEUS initiative is an international, multicenter effort evaluating the performance and utility of OMERACT ultrasound definitions in SpA.
Toward Better Ultrasound Prognosis
Spondyloarthritis is a heterogeneous group that includes axial SpA, peripheral SpA, enthesitis, and overlapping extra-musculoskeletal manifestations. Emerging ultrasound research reports that subclinical enthesitis is common and linked to structural damage, although its prognostic significance still requires longitudinal study. Composite indexes such as the DEI may help integrate objective imaging findings with clinical relevance.
A Heterogeneous Disease Context
Enthesitis must be interpreted within the broader and heterogeneous spectrum of spondyloarthritis. Patients may have axial or peripheral disease alongside manifestations outside the musculoskeletal system. This clinical diversity can make uniform assessment and treatment decisions more challenging.
Patient Burden and Treatment Response
In a US-based real-world study of patients with axial spondyloarthritis, clinical enthesitis was associated with higher disease activity and worse quality of life than its absence. A separate real-world analysis examined the effectiveness of TNFi therapy on enthesitis at locations including the spine, thoracic cage, Achilles tendon, and plantar fascia. Research in 1,505 patients with SpA in Brazil also confirmed enthesitis as a common manifestation across the SpA spectrum.
Furthermore, the study highlights the need for ongoing research to refine enthesitis assessment methods and identify novel therapeutic targets. As our understanding of SpA evolves, personalized treatment approaches that address the specific needs of each patient will become increasingly important.
The insights gained from the ABILITY-2 trial pave the way for more effective and targeted therapies for SpA. By prioritizing enthesitis assessment, we can move closer to a future where individuals with SpA experience improved outcomes and a better quality of life.